IL-10 and TNF-α polymorphisms in subjects with irritable bowel syndrome in Mexico;Polimorfsmos de IL-10 y TNF-α en sujetos con síndrome de intestino irritable en México

Revista Espanola de Enfermedades Digestivas

Volumn 105, Issue 7, 2013, Pages 392-399

  Schmulson, Max ^a   Pulido London, Daniela ^a   Rodríguez, Óscar ^a   Morales Rochlin, Norma ^a   Martínez García, Rosalinda ^a   Gutiérrez Ruiz, María Concepción ^b   López Alvarenga, Juan Carlos ^c   Gutiérrez Reyes, Gabriela ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Constipation; Diarrhea; Genotypes; IL 10; Immunoregulation; Interleukins; Irritable bowel syndrome; Mexico; TNF

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IMMUNOREGULATION; IRRITABLE COLON; PROTEIN POLYMORPHISM; QUESTIONNAIRE; ADULT; FEMALE; GENETIC POLYMORPHISM; GENETICS; MALE; MEXICO;

ADULT; FEMALE; HUMANS; INTERLEUKIN-10; IRRITABLE BOWEL SYNDROME; MALE; MEXICO; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890488965     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082013000700004     Document Type: Article

References (35)

1. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:21-43.
2. Surdea-Blaga T, Baban A, Dumitrascu DL. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 2012;18:616-626.
3. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: patho-physiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011;62:591-599.
4. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gas-troenterology 2009;136:1979-1988.
5. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792-1801.
6. Saulnier DM, Riehle K, Mistretta TA, Díaz MA, Mandal D, Raza S, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-1791.
7. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review. J Gastroen-terol 2011;46:421-431.
8. Schmulson M, Chey WD. Abnormal immune regulation and low-grade infammation in IBS: Does one size ft all? Am J Gastroenterol 2012;107:273-275.
9. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009;136:2003-2014.
10. Schmulson M, Pulido-London D, Rodríguez O, Morales-Rochlin N, Martínez-García R, Gutiérrez-Ruiz MC, et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012;107:747-753.
11. Camilleri M. Genetics and irritable bowel syndrome: from geno-mics to intermediate phenotype and pharmacogenetics. Dig Dis Sci 2009;54:2318-2324.
12. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-1513.
13. Camilleri M, Katzka DA. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacoge-netics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;302:G1075-1084.
14. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009;20:43-59.
15. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an infammatory component? Gut 2003;52:91-93.
16. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516.
17. Ortiz-Lucas M, Saz-Peiro P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: The role of cytokines. Rev Esp Enferm Dig 2010;102:711-717.
18. Bashashati M, Rezaei N, Bashashati H, Shafeyoun A, Daryani NE, Sharkey KA, et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neu-rogastroenterol Motil 2012;24:1102-e566.
19. Schmulson M, Ortiz O, Santiago-Lomeli M, Gutiérrez-Reyes G, Gutié-rrez-Ruiz MC, Robles-Díaz G, et al. Frequency of functional bowel disorders among healthy volunteers in Mexico City. Dig Dis 2006;24:342-347.
20. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999;7:127-128.
21. Lee HJ, Lee S Y, Choi JE, Kim JH, Sung IK, Park HS, et al. G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome. Neurogas-troenterol Motil 2010;22:758-763.
22. Wang BM, Jiang XZ, Yang YL, Liu WT, Cao XC, Zhao XZ. A study of interleukin-10 gene polymorphism in irritable bowel syndrome. Zhonghua Nei Ke Za Zhi 2006;45:289-292.
23. Santhosh S, Dutta AK, Samuel P, Joseph AJ, Ashok Kumar J, Kurian G. Cytokine gene polymorphisms in irritable bowel syndrome in Indian population - a pilot case control study. Trop Gastroenterol 2010;31:30-33.
24. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gas-troenterology 2007;132:913-920.
25. Gecse K, Roka R, Ferrier L, Leveque M, Eutamene H, Cartier C, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591-599.
26. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004;20:1317-1322.
27. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-1294.
28. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-272.
29. Barkhordari E, Rezaei N, Ansaripour B, Larki P, Alighardashi M, Ahmadi-Ashtiani HR, et al. Proinfammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010;30:74-79.
30. Baran W, Szepietowski JC, Mazur G, Baran E. A-308 promoter polymorphism of tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis vulgaris. No difference either between psoriasis type I and type II patients. Acta Dermatovenerol Alp Pano-nica Adriat 2006;15:113-118.
31. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for infammatory bowel disease. Scand J Immunol 1996;43:456-463.
32. De Vries N, Tak PP. The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxford) 2005;44:705-707.
33. Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernández-López JC, Uribe-Figueroa L, Contreras A, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci U S A 2009;106:8611-8616.
34. Wang S, Ray N, Rojas W, Parra MV, Bedoya G, Gallo C, et al. Geographic patterns of genome admixture in Latin American Mestizos. PLoS Genet 2008;4:e1000037.
35. Rodríguez-Fandiño O, Hernández-Ruiz J, López-Vidal Y, Charúa L, Ban-deh-Moghaddam H, Minzoni A, et al. Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response to pathogen-associated molecular patterns stimulation in patients with IBS. Neurogas-troenterol Motil 2013;25:872-e699.